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A B S T R A C T   
Background: New hypertension performance measures encourage more intensive treatment in older adults. 
Treatment intensification includes starting new medications and increasing the dose of old ones. Medication dose 
is particularly important to older adults, given their vulnerability to dose-related side effects. We previously 
validated a standardized measure of beneficial doses tested in hypertension trials, Hypertension Daily Dose 
(HDD). 
Aim of the study: To test whether changes in treatment intensity using HDD was associated with systolic blood 
pressure (SBP) and patient characteristics. 
Methods: Longitudinal study of all Veterans aged ≥65 years with a diagnosis of hypertension. We defined 3 
groups of risk: 1) cardiovascular risk; 2) geriatric/frail; 3) low-risk (comparator). Using multinomial regression, 
we assessed the probability of deintensification, intensification, vs. stable treatment, according to SBP and group. 
Results: Among 1,331,111 Veterans, 19.9% had deintensification, and 29.6% intensification. Deintensification 
decreased, while intensification increased, with SBP. Compared to low-risk patients, cardiovascular risk patients 
had 1.11 (95% CI 1.10–1.13) times the odds of intensifying, and geriatric/frail patients 1.45 (95%CI 1.43–1.47) 
times the odds of deintensifying. 
Discussion: Patient-level HDD change was consistent with an expected association with cardiovascular risk and 
geriatric/frail conditions, suggesting that HDD can be used longitudinally to assess hypertension treatment 
modification in large health systems.   
1. Introduction 
It can be challenging to measure hypertension treatment intensifi-
cation and deintensification for a primary care population for a number 
of reasons. First, many health systems do not have ready access to 
pharmacy records in order to verify what medications are actually 
dispensed. But even for those that do, observed blood pressure is highly 
variable and both medications and doses are changed frequently. There 
are many medication classes and choices within classes, all of which 
have different potency. Previous studies of community populations 
where pharmacy records are available have focused solely on 
medication count or blood pressure (BP) control [1,2]. We desired to 
more precisely study total dose burden over time, an issue particularly 
important for older adults, who are more vulnerable to dose-related and 
polypharmacy-related adverse drug events [3]. 
In prior work focused on only those patients with aggressive hy-
pertension treatment (systolic blood pressure [SBP] <120 mmHg and 
≥3 antihypertensive medications), we developed a new measure to 
assess the intensity of hypertension pharmacological treatment (i.e., 
total daily dose) on any given day based on pharmacy fill data [4,5]. 
Unlike previous methods, this new measure uses standardized doses 
based on trial evidence-based beneficial doses used to treat 
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hypertension. In the present study, we applied this new measure to all 
1.3 million older Veterans with hypertension diagnosis who were 
receiving any level of intensity of hypertension medication treatment, 
from the Veterans Health Administration (VHA) during 2011–2013. The 
risk-benefit tradeoff of BP treatment is most likely to be favorable if the 
degree of treatment intensity is matched to risk of cardiovascular events 
vs. the risk of side effects. Thus, to assess whether our new measure can 
be used to track hypertension treatment intensity using health system 
data, we looked at whether the probability of deintensifying or inten-
sifying was consistent with the expected direction of effect for patients 
with cardiovascular risk and geriatric/frail conditions using our new 
measure. 
2. Methods 
2.1. Patients and setting 
We used administrative and clinical data from all US Veterans Affairs 
(VA) facilities available through the Clinical Data Warehouse (CDW), 
including demographics, healthcare encounters, and VA pharmacy fills. 
CDW data were linked to Medicare Part D pharmacy claims (Department 
of Veterans Affairs, VA Health Services Research and Development 
Service, VA Information Resource Center (#02–237 and 98–004)). This 
research was conducted under Human Subjects review (VA IRB 
2015–286). 
We included all Veterans aged ≥65 years with a diagnosis of hy-
pertension (International Classification of Diseases [ICD]-9 401.x), 
established primary care at the VHA (≥2 visits between July 1, 2009 and 
June 30, 2011), and ≥1 eligible visit during the study period (July 1, 
2011 to June 30, 2013). Eligible visits included all outpatient visits from 
general internal medicine, geriatrics, and specialties managing hyper-
tension (cardiology, endocrinology, nephrology, neurology), during the 
study period. The first visit during the study period was used as baseline 
visit. 
2.2. Outcome 
The primary outcome of interest was one of three possible treatment 
strategies revealed after the baseline visit representing a choice between 
modifying or keeping the same antihypertensive treatment intensity: 1) 
stable treatment (no dose change; reference); 2) deintensification (total 
standardized dose decrease); and 3) intensification (total standardized 
dose increase). We calculated dose change between baseline visit and 90 
days after that visit to determine the treatment strategy. The 90-day time 
frame was chosen because it corresponds to the usual refill period. Pa-
tients who died within 90 days after baseline visit were included only for 
analyses of the baseline measurements, as they could not be assigned a 
treatment strategy. 
To determine the complete antihypertensive medication regimen, we 
extracted data from both VA and Medicare Part D fills, and applied a 
measure that we previously validated in a sample of this Veterans 
population, which uses prefills (within 186 days before a visit) and re-
fills (within 186 days after) to determine the most likely medication 
(name, class, dose) that a patient was receiving on any day (i.e., not only 
visit days) [5]. To allow comparison across all antihypertensive medi-
cations, we defined a standardized moderate daily dose (“Hypertension 
Daily Dose” [HDD]) for each medication, with one HDD corresponding 
to half the maximum beneficial dose demonstrated in hypertension tri-
als, as published in the Joint National Commission (JNC) 7 and 8 and 
American Hospital Association/American College of Cardiology 
(AHA/ACC) guidelines [6–8]. For each patient, the standardized total 
daily dose was obtained by summing the HDDs of each medication. For 
example, a patient on lisinopril 20 mg (half maximal dose: 1 HDD) and 
hydrochlorothiazide 50 mg (maximal dose: 2 HDDs), was assigned 3 
HDDs. 
2.3. Measures 
We defined baseline BP as the mean of BP measured during baseline 
visit and during the last visit before baseline to increase the precision of 
the baseline measurement. We classified patients into three groups 
(Supplemental Text 1). “Cardiovascular risk” comorbidity grouping, 
included patients with conditions increasing the likelihood to benefit of 
intensive antihypertensive treatment (diabetes mellitus, cardiovascular 
disease, congestive heart failure, chronic kidney disease, smoking, 
hyperlipidemia), yet they were free of geriatric/frailty criteria described 
under group 2. “Geriatric/frail” comorbidity grouping, included patients 
with dementia, psychotic disorder, fall risk, osteoporosis, skin ulcer, 
and/or nutritional deficiency. “Healthy/low-risk” grouping, were pa-
tients not included in the previous groups, and was used as reference. 
The three groups were mutually exclusive and defined based on ICD-9 
codes (Supplemental Text 1 and Supplemental Table 1). 
2.4. Statistical analyses 
We described the distribution of HDD and medication count ac-
cording to baseline systolic BP (SBP) and diastolic BP (DBP), respec-
tively. We assessed the incidence of each treatment strategy (i.e., 
deintensification, intensification, stable treatment). We used a multi-
nomial logistic regression analysis to assess the probability of dein-
tensification, intensification, and stable treatment, adjusted for age, 
baseline standardized antihypertensive medication dose, baseline SBP, 
and comorbidity variables not included in the 3 groups above (Supple-
mental Text S2). We assessed separately the 3 group risks (cardiovas-
cular, geriatric/frail, healthy/low-risk). We performed all analyses using 
Stata 15.1 (Stata-Corp LP, College Station, TX, USA), and SAS Enterprise 
Guide 7.1 (SAS Institute). 
3. Results 
3.1. Baseline characteristics 
The sample included 1,331,111 patients, with a mean age of 76.1 (SD 
7.5) years, 98.2% males, and a mean SBP of 129.8 (SD 12.8) mmHg 
(Table 1). Most patients (N = 943,341; 70.9%) had multimorbidity, with 
a mean of 3.5 (SD 3.6) chronic conditions in addition to hypertension. 
One-third (32.2%) had cardiovascular disease, 28.7% had diabetes 
mellitus, and 11.0% had atrial fibrillation or flutter. With respect to the 
Table 1 
Baseline characteristics of the patients (N = 1,331,111).  
Characteristic N (%) or mean (SD) 
Age, years 76.1 (7.5) 
Baseline systolic blood pressure, mmHg 129.8 (12.8) 
<120.0 279,390 (21.0) 
120.5–140.0 829,344 (62.3) 
>140.0 222,377 (16.7) 
Baseline Hypertension Daily Dose 1.9 (1.9) 
Chronic conditions 
- N of conditions in addition to hypertension 3.5 (3.6) 
- Multimorbidity (≥2 chronic conditions) 943,341 (70.9) 
- Diabetes mellitus 382,419 (28.7) 
- Current smoking 124,241 (9.3) 
- Cardiovascular diseasea 428,649 (32.2) 
- Atrial fibrillation or flutter 146,209 (11.0) 
- Chronic kidney disease 156,394 (11.8) 
- Cancer 169,514 (12.7) 
Subgroupb 
- Cardiovascular risk 430,455 (32.3) 
- Geriatric/frail 88,137 (6.6) 
- Healthy/low-risk 812,519 (61.0) 
Abbreviations: N, number; SD, standard deviation. 
a Cardiac, peripheral, and/or cerebral vascular disorder. 
b Details of definition in Supplemental Text 1. 
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comorbidity groupings, 31.4% of the patients were in the cardiovascular 
risk group, 29.0% in the geriatric/frail group, and 39.6% in the healthy/ 
low-risk group. 
3.1.1. Blood pressure control and antihypertensive medication (Fig. 1) 
The SBP was <140 mmHg in 1,108,734 patients (83.3%), including 
279,390 (25.2%) with an SBP <120 mmHg, while the DBP was <90 
mmHg in 97.6% (N = 1,298,662) of the patients. Mean standardized 
medication dose increased with SBP, with a mean HDD of 1.8 (SD 1.8) in 
patients with an SBP <120 mmHg, 1.9 (SD 1.9) in those with an SBP 
120–140 mmHg, and 2.2 (SD 2.2) in those with an SBP >140 mmHg (p 
< 0.001). Overall, 19.1% (N = 253,648) of patients had no antihyper-
tensive medication at baseline, a proportion that was similar across all 
SBP categories. 
3.1.2. Incidence of deintensification and intensification 
Within 90 days of baseline visit, 13,415 (1.0%) patients died and 
could thus not be assigned a treatment strategy. Among the remaining 
patients, 262,238 (19.9%) had deintensification, and 389,351 (29.6%) 
had intensification of their antihypertensive treatment. 59.3% of pa-
tients with deintensification had only a total dose decrease, and 63.2% 
of those with intensification had only a total dose increase, without 
changing the total number of medications, while the remaining 40% had 
changes in the number of medications. 
3.1.3. Factors associated with deintensification and intensification (Fig. 2) 
Deintensification was more likely at lower SBPs, with an adjusted 
probability (95%CI) of 23.8% (23.6–24.0%) at SBP = 100 mmHg, and 
15.8% (15.6–15.9%) at SBP = 160 mmHg. On the other hand, intensi-
fication occurred with an absolute probability of 20.2% (20.1–20.4%) at 
SBP = 100 mmHg, and 40.7% (40.4–40.9%) at SBP = 160 mmHg. 
Consistent with expectation, geriatric/frail patients were treated more 
conservatively, with a higher probability of deintensification, particu-
larly when SBP was low (Fig. 2). They had 1.45 (95%CI 1.43–1.47) times 
the odds of deintensification compared to the healthy/low-risk group. 
Also consistent with expectation, patients at higher cardiovascular risk 
were more likely to intensify than healthy patients, with an OR of 1.11 
(95%CI 1.10–1.12) (Fig. 2). The healthy/low-risk patients were similar 
to cardiovascular risk patients in their likelihood to intensify when SBP 
was above 140 mmHg. 
4. Discussion 
In this large-scale nationwide study using nearly complete pharmacy 
data sources within the largest US healthcare system, we described the 
longitudinal modification in hypertension treatment intensity over time 
in more than 1.3 million older Veterans, using a new more compre-
hensive measure of treatment intensity based on demonstrated benefi-
cial doses in hypertension trials. At three months, 20% and 30% of 
patients had received deintensification or intensification of their anti-
hypertensive medication regimen, respectively. Geriatric/frail patients 
were treated more conservatively, with a higher probability of dein-
tensification, while patients at higher cardiovascular risk were more 
likely to intensify. Healthy/low-risk patients were more likely to dein-
tensify at low SBP, but to intensify at higher SBP. 
At baseline in 2011–2013, 82% of the patients had a BP controlled to 
<140/90 mmHg, corresponding to the treatment goal at that time [9]. 
This result is consistent with often-cited report that 76% of Veterans had 
a SBP <140/90 mmHg in 2010, a yearly improvement in control rates of 
3%, and a level of control better than the rest of the nation [10]. On 
average, each older Veteran was receiving two medications at half the 
maximal beneficial dose, a dose similar to the SPRINT control group’s 
mean medication count [11]. 
Using our new measure to capture treatment intensity modification 
over time, we observed an expected inverse relationship between SBP 
and deintensification, and a positive association of SBP with intensifi-
cation. We also encouragingly found a relationship between baseline 
SBP and change in treatment intensity that varied according to patient 
Fig. 1. Distribution of baseline antihypertensive medication regimen, according to baseline blood pressure in all patients (N = 1,331,111): A) dose and SBP; B) dose 
and DBP; C) medication count and SBP; D) medication count and DBP. 
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comorbidities and cardiovascular risk. Geriatric and frail patients were 
more likely to have their treatment deintensified than healthier patients 
or those at high cardiovascular risk. About 20% of patients at low car-
diovascular risk (group 3) had deintensification when SBP was low 
(<100 mmHg). Clinically, we would expect that providers would be 
more likely to deintensify medication for this low-risk group because 
they understood that they would have less benefit from tight BP control. 
However, they were just as likely as the cardiovascular risk patients to 
be escalated in care if indicated by high SBP. The expected relationship 
that we observed between SBP, comorbidities and treatment modifica-
tion, suggests that our measure is a reliable way to assessing antihy-
pertensive medication intensity in this patient population. 
Our measure assesses both the number and total standardized dose of 
antihypertensive medications using administrative data available 
through the VA electronic medical record and pharmacy database. This 
measure can be adapted to other health systems that can get access to 
both observed BP and prescription fills, with several implications. First, 
total dose burden could supplement traditional measurement of hyper-
tension control by BP values and antihypertensive medication count. 
The continuous measure of medication treatment intensity can track 
more closely than medication counts any changes in the intensity of 
hypertension treatment. Second, it could be used with observational 
data to assess the outcomes of deintensification and intensification of 
antihypertensive medication in patients who were excluded from hy-
pertension trials. Finally, it could be used to evaluate the patterns of 
hypertension treatment (e.g., several medications at low dose or fewer 
medications at higher dose) over time and in response to new evidence 
and quality improvement efforts. 
4.1. Strengths and limitations 
We discuss several limitations. First, this study of older Veterans was 
predominantly males, so that the results may not be generalizable to 
females. Second, because hypertension control has been found to be 
better in Veterans than in the general population (76% vs 50% with BP 
< 140/90 mmHg) [10], it is possible that the predictors of dein-
tensification and intensification may differ from the general older US 
population. Third, pharmacy records do not contain an explicit indica-
tion for changes of antihypertensive medication intensity. We could not 
account for instances where the treatment may have been modified for a 
non-hypertension condition (e.g., arrhythmia control or neurohormonal 
modulation in heart failure), potentially resulting in seemingly para-
doxical clinical actions, e.g, patients with low SBP receiving an “inten-
sification” or patients with high SBP receiving a “deintensification”. 
Fourth, some patients with high BP may have appeared to be dein-
tensified but were actually non-adherent resulting in a decrease in 
HDDs. Finally, pharmacy fills do not directly measure actual day-to-day 
variation in medication consumption or lack of adherence to prescribed 
and filled regimens. Our measure is able to infer the likely decrease in 
consumption when patients delay their refills or cease to refill them [12, 
13], and other studies have demonstrated that pharmacy fills are a 
reliable method to assess medication consumption [14,15]. 
This study has several strengths as well. First, we had access to a 
near-universal medication data source (both VA and Medicare pharmacy 
fills) in a very large national sample of patients across all US regions 
being cared for in the largest US healthcare system. Second, we used a 
measure that assesses both medication count and standardized dose that 
we validated in a sample of this Veterans population [12,13], and we 
were able to study the longitudinal patterns of treatment. Third, we 
averaged two measurements of SBP to define baseline SBP, thus 
reducing measurement error in a key covariate. Finally, we used 
objective data (including ICD-9 codes and laboratory data, and ac-
counting for date of diagnosis) to categorize the patients into three 
subgroups of risk related to the probability to deintensify or intensify 
hypertension treatment. 
5. Conclusion 
This study provides the first longitudinal insight into specific pat-
terns of hypertension treatment intensity among 1.3 million older Vet-
erans across a national healthcare system with respect to comorbidities 
and cardiovascular risk. In addition, changes in HDD were consistent 
with an expected direction of effect with cardiovascular risk and geri-
atric/frail conditions, thus suggesting that HDD can be used longitudi-
nally to assess hypertension treatment modification for patients in large 
health systems. 
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